Clinical Trials on Severe in Czechia

Total 53 results

Mitsubishi Tanabe Pharma Corporation

Completed

PK Study in Subjects With Severe Hepatic Impairment (MCI-186-E05 HP)

Healthy | Severe Hepatic Impairment

Czechia, Hungary, Slovakia
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease

Healthy Subjects | Severe Renal Impairment

Czechia
Brno University Hospital

Unknown

Early Identification of Sepsis in Children

Sepsis | Shock, Septic | SIRS | Sepsis, Severe

Czechia
Brno University Hospital

Recruiting

Corticosteroids in Severe COVID-19(ASAP-C Study) (ASAP-C)

Severe COVID-19

Czechia
University Hospital Ostrava

Completed

Control of Fever in Septic Patients (COVERSEP)

Sepsis | Septic Shock | Severe Sepsis

Czechia
Brno University Hospital
European Society of Intensive Care Medicine; European Society of Anaesthesiology...

Completed

Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study) (ASAPESICMESAIC)

Severe COVID-19

Czechia
Brno University Hospital
Masaryk University

Completed

Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia (MHCZECH)

Malignant Hyperthermia

Czechia
Biocon Biologics Inc.
MEDA Pharma GmbH & Co. KG; Mylan Inc.; IQVIA Pvt. Ltd

Completed

Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity

Moderate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis

Bulgaria, Czechia, Estonia, Poland
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (TRANSFIGURE)

Moderate to Severe Nail Psoriasis

Germany, Belgium, Spain, United States, Australia, United Kingdom, Denmark, Czechia, Greece
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

Psoriasis | Moderate to Severe Plaque Psoriasis

Czechia, Estonia, Hungary, Korea, Republic of, Latvia, Lithuania, Poland, Ukraine
Nemocnice Břeclav, p.o.

Unknown

Roux-en-Y Gastric Bypass (RYGB) Versus Omega-Loop Gastric Bypass (OLGB) Safety and Efficacy Short-term Study (ROSESS)

Diabetes Mellitus, Type 2 | Obesity, Severe

Czech Republic
89bio, Inc.

Completed

Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia

Severe Hypertriglyceridemia

United States, Czechia, Hungary, Poland
AstraZeneca

Completed

Characterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to be Eligible for Biological Therapy (RECOGNISE)

Severe Asthma

Hungary, Germany, Bulgaria, Czechia, France, Greece, Italy, Netherlands, Poland, Romania, Slovenia, Spain
Novartis Pharmaceuticals

Completed

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

Belgium, Spain, Russian Federation, Germany, United States, Czechia, Peru, Poland, Estonia
Ionis Pharmaceuticals, Inc.

Recruiting

A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Severe Hypertriglyceridemia

United States, South Africa, Spain, Israel, Australia, Sweden, Netherlands, Canada, Poland, Denmark, Hungary, Bulgaria, Czechia, Italy, France, Norway, New Zealand, Slovakia, Turkey
AbbVie (prior sponsor, Abbott)

Completed

Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

Moderate to Severe Plaque Psoriasis

Czech Republic, Estonia, Hungary, Israel, Romania, Slovakia, Slovenia, Ukraine
Fresenius Kabi SwissBioSim GmbH

Completed

MSB11022 in Moderate to Severe Rheumatoid Arthritis (Auriel-RA)

Moderate to Severe Rheumatoid Arthritis

Bulgaria, United Kingdom, Hungary, Czechia, Poland, Germany
medac GmbH

Recruiting

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

Moderate to Severe Atopic Dermatitis

France, Poland, Italy, Czechia
89bio, Inc.

Recruiting

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (ENTRUST)

Severe Hypertriglyceridemia

United States, Bulgaria, Canada, Latvia, Spain, Austria, Belgium, Czechia, Georgia, Hungary, Poland, Puerto Rico, Argentina, Chile, France, Germany, United Kingdom, India, Italy
Kowa Research Institute, Inc.

Completed

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

Severe Hypertriglyceridemia

United States, Hungary, Belarus, Bulgaria, Czechia, Georgia, Poland, Russian Federation, Ukraine
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Ionis Pharmaceuticals, Inc.

Recruiting

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Severe Hypertriglyceridemia

United States, Belgium, Spain, Poland, Taiwan, France, Bulgaria, Netherlands, Brazil, Italy, Czechia, Canada, Greece, Portugal, Argentina, Malaysia, Mexico, Slovakia, Sweden, Hungary, India, Romania, Lithuania
Ionis Pharmaceuticals, Inc.

Active, not recruiting

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Severe Hypertriglyceridemia

Finland, United States, France, Israel, Netherlands, Denmark, Spain, Australia, United Kingdom, Germany, Italy, Canada, Czechia, Turkey, Hungary, Bulgaria, New Zealand, Sweden, South Africa, Poland, Norway, Portugal, Slovakia
Bausch Health Americas, Inc.

Terminated

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2)

Moderate to Severe Plaque Psoriasis

United States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Sensorion

Completed

Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss (AUDIBLE-S)

Severe Sudden Sensorineural Hearing Loss

Israel, United Kingdom, France, Serbia, Bulgaria, Canada, Czechia, Germany, Slovakia, Turkey
Fresenius Kabi SwissBioSim GmbH
Merck KGaA, Darmstadt, Germany

Completed

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis (AURIEL-PsO)

Psoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type Psoriasis

United States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
Novartis
Novartis Vaccines

Completed

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Japanese Encephalitis | Rabies | Yellow Fever | Meningococcal Disease | Typhoid | Meningococcal Meningitis

Czech Republic, Germany
Eisai Inc.

Completed

ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis

Severe Sepsis

United States, France, Poland, United Kingdom, Germany, Hong Kong, Taiwan, Spain, Switzerland, Argentina, Belgium, Israel, South Africa, Japan, Canada, Netherlands, Korea, Republic of, Australia, Chile, Brazil, Austria, Italy, Czechia, Portug...
Swedish Orphan Biovitrum
Syneos Health

Active, not recruiting

A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa (FREEDOM)

Hemophilia A, Severe

Germany, Spain, France, Czechia, Netherlands, Ireland, Austria, Croatia, Greece, Italy, Norway, Slovenia, Sweden, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

United States, Hungary, Italy, Russian Federation, Germany, Czechia, Canada
AstraZeneca

Completed

A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock

Septic Shock | Severe Sepsis

Czech Republic, France, Spain, Finland, Canada, Australia, Belgium
Abbott Medical Devices

Active, not recruiting

The CONFIDENCE Registry

Severe Aortic Stenosis | Symptomatic Degenerative Aortic Stenosis

Spain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
Santen SAS

Completed

3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)

Dry Eye Disease With Severe Keratitis

Czechia, France, Italy, Poland, Russian Federation, Spain, Turkey
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

Moderate to Severe Plaque-type Psoriasis

United States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
Kowa Research Institute, Inc.

Completed

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

Severe Hypertriglyceridemia

United States, Czechia, Belarus, Hungary, Russian Federation, Poland, Bulgaria, Georgia, Ukraine
Edwards Lifesciences

Completed

SOURCE XT REGISTRY

Severe Aortic Stenosis

Spain, Italy, Canada, Belgium, Greece, Germany, Austria, United Kingdom, Finland, Denmark, France, Switzerland, Israel, Poland, South Africa, Czechia, Netherlands, Norway
Amgen

Completed

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG)

Severe Familial Hypercholesterolemia

Italy, Czechia, United States, Israel, New Zealand, South Africa, France, Spain, Australia, Belgium, Canada, Netherlands, Hong Kong, Brazil, United Kingdom, Greece, Japan, Lebanon
Cytos Biotechnology AG

Terminated

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

Moderate to Severe Allergic Asthma

United States, Czech Republic, Germany, Hungary, Israel, Poland, Russian Federation, Ukraine
Mundipharma Research GmbH & Co KG

Completed

A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain

Parkinson's Disease With Severe Pain

United Kingdom, Spain, Germany, Hungary, Czech Republic, Poland, Romania
CSL Behring

Completed

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

Hemophilia A | Severe Hemophilia A

United States, Australia, Austria, Canada, Czechia, France, Georgia, Germany, Hungary, Ireland, Italy, Japan, Lebanon, Malaysia, Netherlands, Philippines, Poland, Portugal, Romania, South Africa, Spain, Switzerland, Thailand, Ukraine, United...
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Completed

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland
Nektar Therapeutics

Recruiting

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

Moderate to Severe Atopic Dermatitis

Spain, Czechia, United States, Australia, Croatia, Bulgaria, Poland, Canada, Germany, Hungary
Asahi Kasei Pharma America Corporation

Completed

Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Severe Sepsis | Coagulopathy

Korea, Republic of, United States, Taiwan, Netherlands, United Kingdom, Australia, Canada, Belgium, Israel, Spain, New Zealand, France, Brazil, India, Argentina, Bulgaria, Croatia, Czechia, Finland, Germany, Hungary, Peru, Russian Federation and more
Galderma R&D

Completed

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

United States, Australia, Austria, Canada, Czechia, Germany, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Spain, United Kingdom
AstraZeneca
MedImmune LLC

Completed

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (GALATHEA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
Galderma R&D

Active, not recruiting

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Singapore, Spain, United Kingdom
European Organisation for Research and Treatment...

Completed

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Unspecified Adult Solid Tumor, Protocol Specific | Infection | Multiple Myeloma and Plasma Cell Neoplasm | Fever, Sweats, and Hot Flashes | Bone Marrow Suppression

Switzerland, United States, Canada, United Kingdom, Belgium, Israel, Slovakia, Finland, Germany, France, Turkey, Czech Republic, Greece
European Organisation for Research and Treatment...

Completed

Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients

Cancer

Belgium, Netherlands, Italy, Hungary, France, Spain, Germany, Israel, Czech Republic, United Arab Emirates, Sweden, Greece, Turkey, Portugal, Slovakia
Novartis Pharmaceuticals

Completed

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)

Malignant Melanoma

Canada, Italy, Czechia, Australia, France, Greece, Israel, Russian Federation, Sweden, United Kingdom, Hungary, Slovakia, Slovenia, Japan, Turkey, Argentina, Finland, Norway, Brazil, Latvia, Lithuania, Poland, Portugal
Amgen

Completed

Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy

Chemotherapy-induced Febrile Neutropenia

Belgium, Poland, Germany, Czechia, Austria, France, Greece, Romania, Bulgaria

Clinical Trials on Severe in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations